Promoting regulation via the inhibition of DNAM-1 after transplantation

Blood

Volumn 121, Issue 17, 2013, Pages 3511-3520

  Koyama, Motoko ^a   Kuns, Rachel D ^a   Olver, Stuart D ^a   Lineburg, Katie E ^a   Lor, Mary ^a   Teal, Bianca E ^a   Raffelt, Neil C ^a   Leveque, Lucie ^a   Chan, Christopher J ^b,c,d   Robb, Renee J ^a   Markey, Kate A ^a   Alexander, Kylie A ^a   Varelias, Antiopi ^a   Clouston, Andrew D ^e   Smyth, Mark J ^b,c,d   MacDonald, Kelli P A ^a   Hill, Geoffrey R ^a,f  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e Envoi Pathology   (Australia)

^f ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CELL ADHESION MOLECULE; DNAX ACCESSORY MOLECULE 1; MINOR HISTOCOMPATIBILITY ANTIGEN; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG; CD226 ANTIGEN; CYTOKINE; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, MOUSE; T LYMPHOCYTE ANTIGEN;

ALLOGENIC BONE MARROW TRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; GRAFT VERSUS HOST REACTION; MAJOR HISTOCOMPATIBILITY COMPLEX; MIXED LYMPHOCYTE REACTION; MOUSE; MYELOABLATIVE CONDITIONING; NATURAL KILLER CELL; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; WHOLE BODY RADIATION; ANIMAL; BAGG ALBINO MOUSE; BONE MARROW TRANSPLANTATION; C3H MOUSE; C57BL MOUSE; CHEMISTRY; EXPERIMENTAL LEUKEMIA; GRAFT VERSUS LEUKEMIA EFFECT; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; METABOLISM; MOUSE MUTANT; PHYSIOLOGY; TUMOR CELL CULTURE;

ANIMALS; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; BONE MARROW TRANSPLANTATION; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYTOKINES; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GRAFT VS HOST DISEASE; GRAFT VS LEUKEMIA EFFECT; LEUKEMIA, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; MICE, INBRED C57BL; MICE, KNOCKOUT; T-LYMPHOCYTES, REGULATORY; TRANSPLANTATION CONDITIONING; TUMOR CELLS, CULTURED; WHOLE-BODY IRRADIATION;

MLCS; MLOWN;

EID: 84879346990     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-07-444026     Document Type: Article

References (47)

1. Ferrara JL, Levine JE, Reddy P, Holler E. Graft-versus-host disease. Lancet. 2009;373(9674): 1550-1561.
2. Shlomchik WD. Graft-versus-host disease. Nat Rev Immunol. 2007;7(5):340-352.
3. Shlomchik WD, Couzens MS, Tang CB, et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science. 1999;285(5426):412-415.
4. Koyama M, Kuns RD, Olver SD, et al. Recipient nonhematopoietic antigen-presenting cells are sufficient to induce lethal acute graft-versus-host disease. Nat Med. 2011;18(1):135-142.
5. Bottino C, Castriconi R, Pende D, et al. Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule. J Exp Med. 2003;198(4):557-567.
6. Tahara-Hanaoka S, Shibuya K, Kai H, et al. Tumor rejection by the poliovirus receptor family ligands of the DNAM-1 (CD226) receptor. Blood. 2006;107(4):1491-1496.
7. Chan CJ, Andrews DM, Smyth MJ. Receptors that interact with nectin and nectin-like proteins in the immunosurveillance and immunotherapy of cancer. Curr Opin Immunol. 2012;24(2):246-251.
8. Shibuya A, Campbell D, Hannum C, et al. DNAM-1, a novel adhesion molecule involved in the cytolytic function of T lymphocytes. Immunity. 1996;4(6):573-581.
9. Dardalhon V, Schubart AS, Reddy J, et al. CD226 is specifically expressed on the surface of Th1 cells and regulates their expansion and effector functions. J Immunol. 2005;175(3):1558-1565.
10. Cho D, Shook DR, Shimasaki N, Chang YH, Fujisaki H, Campana D. Cytotoxicity of activated natural killer cells against pediatric solid tumors. Clin Cancer Res. 2010;16(15):3901-3909.
11. Sanchez-Correa B, Gayoso I, Bergua JM, Casado JG, Morgado S, Solana R, Tarazona R. Decreased expression of DNAM-1 on NK cells from acute myeloid leukemia patients. Immunol Cell Biol. 2012;90(1):109-115.
12. Cella M, Presti R, Vermi W, et al; CHAVI Clinical Core B; NIAID Center for HIV/AIDS Vaccine Immunology. Loss of DNAM-1 contributes to CD81 T-cell exhaustion in chronic HIV-1 infection. Eur J Immunol. 2010;40(4):949-954.
13. Stegmann KA, Björkström NK, Ciesek S, et al. Interferon a-stimulated natural killer cells from patients with acute hepatitis C virus (HCV) infection recognize HCV-infected and uninfected hepatoma cells via DNAX accessory molecule-1. J Infect Dis. 2012;205(9):1351-1362.
14. Hafler JP, Maier LM, Cooper JD, et al; International Multiple Sclerosis Genetics Consortium (IMSGC). CD226 Gly307Ser association with multiple autoimmune diseases. Genes Immun. 2009;10(1):5-10.
15. Todd JA, Walker NM, Cooper JD, et al; Genetics of Type 1 Diabetes in Finland; Wellcome Trust Case Control Consortium. Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes. Nat Genet. 2007; 39(7):857-864.
16. Yu X, Harden K, Gonzalez LC, et al. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nat Immunol. 2009;10(1):48-57.
17. Stanietsky N, Simic H, Arapovic J, et al. The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity. Proc Natl Acad Sci USA. 2009;106(42):17858-17863.
18. Joller N, Hafler JP, Brynedal B, et al. Cutting edge: TIGIT has T cell-intrinsic inhibitory functions. J Immunol. 2011;186(3):1338-1342.
19. Levin SD, Taft DW, Brandt CS, et al. Vstm3 is a member of the CD28 family and an important modulator of T-cell function. Eur J Immunol. 2011; 41(4):902-915.
20. Gilfillan S, Chan CJ, Cella M, et al. DNAM-1 promotes activation of cytotoxic lymphocytes by nonprofessional antigen-presenting cells and tumors. J Exp Med. 2008;205(13):2965-2973.
21. Fontenot JD, Rasmussen JP, Williams LM, Dooley JL, Farr AG, Rudensky AY. Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity. 2005;22(3): 329-341.
22. Robb RJ, Kreijveld E, Kuns RD, et al. Type I-IFNs control GVHD and GVL responses after transplantation. Blood. 2011;118(12):3399-3409.
23. Hill GR, Crawford JM, Cooke KR, Brinson YS, Pan L, Ferrara JL. Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood. 1997;90(8):3204-3213.
24. Burman AC, Banovic T, Kuns RD, et al. IFNgamma differentially controls the development of idiopathic pneumonia syndrome and GVHD of the gastrointestinal tract. Blood. 2007;110(3): 1064-1072.
25. Nabekura T, Shibuya K, Takenaka E, et al. Critical role of DNAX accessory molecule-1 (DNAM-1) in the development of acute graft-versus-host disease in mice. Proc Natl Acad Sci USA. 2010; 107(43):18593-18598.
26. Nguyen VH, Zeiser R, Dasilva DL, Chang DS, Beilhack A, Contag CH, Negrin RS. In vivo dynamics of regulatory T-cell trafficking and survival predict effective strategies to control graft-versus-host disease following allogeneic transplantation. Blood. 2007;109(6):2649-2656.
27. Lozano E, Dominguez-Villar M, Kuchroo V, Hafler DA. The TIGIT/CD226 axis regulates human T cell function. J Immunol. 2012;188(8): 3869-3875.
28. Chan CJ, Andrews DM, McLaughlin NM, Yagita H, Gilfillan S, Colonna M, Smyth MJ. DNAM-1/ CD155 interactions promote cytokine and NK cell-mediated suppression of poorly immunogenic melanoma metastases. J Immunol. 2010;184(2): 902-911.
29. Blazar BR, Murphy WJ, Abedi M. Advances in graft-versus-host disease biology and therapy. Nat Rev Immunol. 2012;12(6):443-458.
30. Herrera C, Torres A, García-Castellano JM, et al. Prevention of graft-versus-host disease in high risk patients by depletion of CD41 and reduction of CD81 lymphocytes in the marrow graft. Bone Marrow Transplant. 1999;23(5):443-450.
31. Nimer SD, Giorgi J, Gajewski JL, et al. Selective depletion of CD81 cells for prevention of graft-versus-host disease after bone marrow transplantation. A randomized controlled trial. Transplantation. 1994;57(1):82-87.
32. Seth S, Ravens I, Lee CW, et al. Absence of CD155 aggravates acute graft-versus-host disease. Proc Natl Acad Sci U S A. Mar 8 2011; 108(10):E32-33; author reply E34.
33. Cohen JL, Trenado A, Vasey D, Klatzmann D, Salomon BL. CD4(1)CD25(1) immunoregulatory T Cells: new therapeutics for graft-versus-host disease. J Exp Med. 2002;196(3):401-406.
34. Taylor PA, Lees CJ, Blazar BR. The infusion of ex vivo activated and expanded CD4(1)CD25(1) immune regulatory cells inhibits graft-versus-host disease lethality. Blood. 2002;99(10):3493-3499.
35. Edinger M, Hoffmann P, Ermann J, Drago K, Fathman CG, Strober S, Negrin RS. CD41 CD251 regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med. 2003;9(9):1144-1150.
36. Matte CC, Cormier J, Anderson BE, et al. Graft-versus-leukemia in a retrovirally induced murine CML model: mechanisms of T-cell killing. Blood. 2004;103(11):4353-4361.
37. Pan L, Teshima T, Hill GR, et al. Granulocyte colony-stimulating factor-mobilized allogeneic stem cell transplantation maintains graft-versus-leukemia effects through a perforin-dependent pathway while preventing graft-versus-host disease. Blood. 1999;93(12):4071-4078.
38. Markey KA, Burman AC, Banovic T, et al. Soluble lymphotoxin is an important effector molecule in GVHD and GVL. Blood. 2010;115(1):122-132.
39. Morris ES, MacDonald KP, Rowe V, et al. NKT cell-dependent leukemia eradication following stem cell mobilization with potent G-CSF analogs. J Clin Invest. 2005;115(11):3093-3103.
40. Teshima T, Hill GR, Pan L, Brinson YS, van den Brink MR, Cooke KR, Ferrara JL. IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation. J Clin Invest. 1999;104(3):317-325.
41. Molldrem JJ, Lee PP, Wang C, Felio K, Kantarjian HM, Champlin RE, Davis MM. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med. 2000;6(9):1018-1023.
42. Rezvani K, Yong AS, Savani BN, et al. Graft-versus-leukemia effects associated with detectable Wilms tumor-1 specific T lymphocytes after allogeneic stem-cell transplantation for acute lymphoblastic leukemia. Blood. 2007;110(6): 1924-1932.
43. Battaglia M, Stabilini A, Roncarolo MG. Rapamycin selectively expands CD41CD251 FoxP31 regulatory T cells. Blood. 2005;105(12): 4743-4748.
44. Coenen JJ, Koenen HJ, van Rijssen E, Kasran A, Boon L, Hilbrands LB, Joosten I. Rapamycin, not cyclosporine, permits thymic generation and peripheral preservation of CD41 CD251 FoxP31 T cells. Bone Marrow Transplant. 2007;39(9): 537-545.
45. Gao W, Lu Y, El Essawy B, Oukka M, Kuchroo VK, Strom TB. Contrasting effects of cyclosporine and rapamycin in de novo generation of alloantigen-specific regulatory T cells. Am J Transplant. 2007;7(7):1722-1732.
46. Tang Q, Henriksen KJ, Bi M, et al. In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J Exp Med. 2004; 199(11):1455-1465.
47. Koreth J, Matsuoka K, Kim HT, et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med. 2011;365(22): 2055-2066.